NeurAxis, Inc. (NASDAQ: NRXS) is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for neurodegenerative and neurological disorders. The company’s primary focus lies in targeting key pathways involved in protein misfolding and neuroinflammation to address diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis and amyotrophic lateral sclerosis. By combining small molecule discovery with targeted antibody therapies, NeurAxis aims to halt or reverse neuronal damage at the molecular level.
NeurAxis’s pipeline features multiple preclinical and early clinical candidates. Its lead program employs a proprietary monoclonal antibody designed to clear pathological protein aggregates associated with dementia, while a series of small-molecule modulators aim to restore disrupted cellular signaling in demyelinating conditions. In addition to therapeutic development, the company is advancing novel imaging tracers to enable earlier diagnosis and more accurate tracking of disease progression.
Founded in 2010 and headquartered in San Diego, California, NeurAxis has established research collaborations with academic centers at the University of California, San Francisco and Harvard Medical School, as well as strategic partnerships with European contract development and manufacturing organizations. Through these alliances, the company extends its reach across North America and Europe, leveraging global expertise in translational neuroscience and scalable manufacturing.
Under the leadership of CEO Jane Smith, Ph.D., a veteran neuroscientist with over 20 years of drug discovery experience, and CFO Michael Chen, NeurAxis emphasizes rigorous clinical validation and patient-centric development. The company’s management team combines industry veterans and scientific innovators, united by a mission to deliver breakthrough therapies that address unmet needs in neurology while maintaining the highest standards of safety and efficacy.
AI Generated. May Contain Errors.
